Ruxolitinib
Pre-clinicalActive 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Myelofibrosis (PMF)
Conditions
Primary Myelofibrosis (PMF), Post Polycythemia Myelofibrosis (PPV MF), Thrombocythemia Myelofibrosis (PET-MF), Severe/Very Severe COVID-19 Illness, Polycythemia Vera (PV), Steroid Refractory Acute Graft Versus Host Disease (SR aGVHD), Steroid Refractory Chronic Graft Versus Host Disease (SR cGVHD)
Trial Timeline
— → —
NCT ID
NCT04745637About Ruxolitinib
Ruxolitinib is a pre-clinical stage product being developed by Novartis for Primary Myelofibrosis (PMF). The current trial status is active. This product is registered under clinical trial identifier NCT04745637. Target conditions include Primary Myelofibrosis (PMF), Post Polycythemia Myelofibrosis (PPV MF), Thrombocythemia Myelofibrosis (PET-MF).
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (16)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05269771 | Pre-clinical | Completed |
| NCT04745637 | Pre-clinical | Active |
| NCT04337359 | Pre-clinical | Completed |
| NCT06824103 | Approved | Recruiting |
| NCT06462469 | Approved | Recruiting |
| NCT03491215 | Phase 1/2 | Completed |
| NCT02966353 | Phase 2 | Completed |
| NCT02292446 | Phase 3 | Completed |
| NCT02091752 | Phase 2 | Terminated |
| NCT02049450 | Phase 2 | Completed |
| NCT02072057 | Phase 2 | Terminated |
| NCT02015208 | Phase 1/2 | Completed |
| NCT02087059 | Phase 3 | Completed |
| NCT01877005 | Phase 2 | Completed |
| NCT01317875 | Phase 1 | Completed |
| NCT01392443 | Phase 2 | Completed |
Competing Products
20 competing products in Primary Myelofibrosis (PMF)